Cover Image

Handbook of drug-eluting stents /

Bibliographic Details
Other Authors: Serruys, P. W., Gershlick, A. H.
Format: Book
Language:English
Published: London ; New York : Taylor & Francis, 2005.
Subjects:
Coronary Restenosis > surgery.
Stents.
Coronary Restenosis > prevention & control.
Vascular Surgical Procedures.
Drug Delivery Systems.
Myocardial Revascularization.
Table of Contents:
  • Restenosis following percutaneous coronary interventions : a clinical problem
  • Histopathology of restenosis
  • Cellular mechanisms of restenosis : conventional dogma and novel theory
  • Molecular basis of restenosis and potential therapeutic targets
  • Principles of continuum pharmacokinetics in stent-based drug elution
  • Importance of the toxic/therapeutic window
  • Drug delivery coastings
  • The importance of the drug platform : coated, uncoated, sleeves, and new concepts
  • Rapamycin structure and mechanism of action
  • Sirolimus-coated stent : preclinical studies
  • Nonrandomized registries for de novo lesions (FIM) and in-stent restenosis
  • The RAVEL trial
  • The SIRIUS, E-SIRIUS, and C-SIRIUS trials
  • Sirolimus-eluting coronary sent in high-risk patients with complex lesions : subset data from controlled clinical trials and registries
  • Local vascular delivery of paclitaxel : background, mechanisms, and pharmacodynamic properties
  • Preclinical experience with the paclitaxel-eluting stent : the Boston scientific program
  • The Quanam drug-eluting stent and the SCORE trial
  • Initial experiences with paclitaxel-eluting stents for treatement of de novo as well as in-stent restenotic lesions : TAXUS I and TAXUS III
  • The Boston scientific taxus trials
  • Local delivery of paclitaxel as a stent coating : biology and clinical implications
  • Asian paclitaxel-eluting stent clinical trail (ASPECT)
  • PATENCY pilot study : a negative trial, in context
  • Paclitaxel-eluting stents-the ELUTES trial
  • Vascular endothelial growth factor (VEGF)-eluting stents
  • The millennium matrix coronary stent
  • The conor drug delivery stent
  • Actinomycin-eluting stent for coronary revascularization : a randomized feasibility and safety study (the ACTION trial)
  • Guidant deliver II study : prospective, nonrandomized, multicenter evaluation of the ACHIEVE paclitaxel-eluting coronary stent system in the treatment of lesions with high risk of revascularization due to restenosis
  • Guidant deliver clinical trial : prospective, randomized, single-blinded, parallel-group (two-arm), multicenter, clinical evaluation of the RX ACHIEVE drug-eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions
  • Batimastat : mode of action, preclinical, and clinical studies
  • The prevention and treatment of in-stent restenosis-the current challenge for coronary intervention
  • Dexamethasone : mode of action, preclinical, and clinical studies
  • 17 beta-estradiol-eluting stents-a potential therapy in the prevention of restenosis
  • An advanced antisense (AVI-4126) for local and stent-based delivery for prevention of restenosis after PCI (current status and future developments)
  • The endeavor drug-eluting stent program
  • Terumo statin releasing stent (perclinical results)
  • Duraflex drug-eluting coronary stent system
  • Genous bio-engineered R stent : development and the HEALING clinical evaluations
  • Everolimus-eluting stents
  • Contemporary state of drug-eluting stents